University of Western Australia School of Medicine and Pharmacology, Sir Charles Gairdner Hospital, Perth, WA, Australia.
Med J Aust. 2009 Nov 16;191(10):539-43. doi: 10.5694/j.1326-5377.2009.tb03306.x.
To compare the use of evidence-based pharmacological and invasive treatments and 12-month mortality rates between patients with and without diabetes who present with acute myocardial infarction (MI), and to explore the relationship between these treatments and late clinical outcomes.
Prospective, nationwide multicentre registry: the Acute Coronary Syndrome Prospective Audit (ACACIA).
Patients presenting to 24 metropolitan and 15 non-metropolitan hospitals with acute coronary syndrome (ACS) and a final discharge diagnosis of acute MI between November 2005 and July 2007.
All-cause mortality at 12 months.
Nearly a quarter of 1744 patients with a final diagnosis of acute MI had a history of diabetes on presentation. Patients with diabetes were older, with a greater prevalence of comorbidities than non-diabetic patients, and were less likely to be treated at discharge with evidence-based medications (aspirin, clopidogrel, a statin and/or a beta-blocker) or to receive early invasive procedures. After adjusting for baseline characteristics and therapeutic interventions, diabetes at presentation was independently associated with a higher mortality at 12 months after MI (hazard ratio, 1.79; 95% CI, 1.18-2.72; P=0.007). Early invasive management and discharge prescription of guideline-recommended medications were associated with a significantly reduced hazard of mortality at 12 months.
Patients with diabetes have a higher risk than non-diabetic patients of late mortality following an acute MI, yet receive fewer guideline-recommended medications and early invasive procedures. Increased application of proven pharmacotherapies and an early invasive management strategy in patients with diabetes presenting with ACS might improve their outcomes. STUDY PROTOCOL NUMBER (SANOFI-AVENTIS): PML-0051.
比较患有和不患有糖尿病的急性心肌梗死(MI)患者在使用循证药理学和介入治疗以及 12 个月死亡率方面的差异,并探讨这些治疗方法与晚期临床结局之间的关系。
前瞻性、全国性多中心登记研究:急性冠状动脉综合征前瞻性审核(ACACIA)。
2005 年 11 月至 2007 年 7 月期间,24 家大都市医院和 15 家非大都市医院收治的急性冠状动脉综合征(ACS)患者,最终出院诊断为急性 MI。
12 个月的全因死亡率。
在最终诊断为急性 MI 的 1744 例患者中,近四分之一的患者在就诊时患有糖尿病。与非糖尿病患者相比,糖尿病患者年龄更大,合并症更多,出院时接受循证药物(阿司匹林、氯吡格雷、他汀类药物和/或β受体阻滞剂)治疗的可能性更小,早期接受介入治疗的可能性也更小。在调整了基线特征和治疗干预措施后,就诊时患有糖尿病与 MI 后 12 个月的死亡率升高独立相关(危险比,1.79;95%置信区间,1.18-2.72;P=0.007)。早期介入管理和出院时开具指南推荐的药物与 12 个月死亡率显著降低相关。
与非糖尿病患者相比,患有糖尿病的急性 MI 患者有更高的晚期死亡风险,但接受的指南推荐药物和早期介入治疗更少。在患有糖尿病的 ACS 患者中,更多地应用已证实的药物治疗和早期介入治疗策略可能会改善他们的结局。研究方案编号(赛诺菲-安万特):PML-0051。